Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04574856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 2026 to Nov 19, 2026
    • Study completion date: Oct 2026 to Nov 19, 2027
    v10
  2. Primary and study completion dates: Oct 2025 to Oct 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  3. Primary and study completion dates: Feb 2025 to Oct 2025v8
  4. Primary and study completion dates: Nov 2024 to Feb 2025v7
  5. Primary and study completion dates: Jul 2024 to Nov 2024v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary and study completion dates: Jan 2024 to Jul 2024v5
  2. 2 versions Re-verified since Dec 16, 2021, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Dec 2023 to Jan 2024
    • Start date changed from estimate of Oct 2020 to Nov 4, 2020
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.
Trial Details
NCT Number NCT04574856
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Glioblastoma
Related terms Glioblastoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov